Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study

Abstract

Relative dose intensity (RDI) has been associated with improved survival in patients with advanced solid tumours. However, there is no evidence regarding RDI in patients under long-term treatment with trabectedin for adult advanced soft tissue sarcoma (STS). Pegfilgrastim use was associated with chemotherapy dose intensity maintenance in patients with various cancers. We retrospectively evaluated the RDI in patients with STS receiving trabectedin. The patients were grouped based on whether trabectedin administration was supported by pegfilgrastim. RDI was obtained for 114 of the 140 included patients. Chemotherapy cycles that included filgrastim were excluded. Patients treated with and without pegfilgrastim had similar RDI rates (77.1% ± 17.6% vs 78.8% ± 16.4%; P = 0.485). Moreover, we found no association between patients receiving ≥4 trabectedin cycles and the use of pegfilgrastim. These results suggested that trabectedin dose delays or reductions should be considered before administering prophylactic pegfilgrastim.

Keywords:

• Adverse event
• pegfilgrastim
• relative dose intensity
• soft tissue sarcoma
• supportive care
• trabectedin

Acknowledgment

We would like to thank Editage (www.editage.com) for English language editing.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics approval

This study was approved by the Institutional Review Board of the National Cancer Center Japan (No. 2020-443).

Author contributions

Y.S. conceptualized and designed the study, collected the data, conducted the initial analysis, and drafted the initial manuscript; T.S., S.I. and A.M. conceptualized and designed the study; T.S., S.I., A.M., K.A., R.U., K.Y., T.F. and F.W. reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.